A View LCS vs qXR-CTR
AI Verdict
Choose A View LCS if…
Choose A View LCS if your clinical workflow requires a comprehensive, AI-powered analysis of thoracic CT scans. This tool is ideal for detailed lung cancer screening, including nodule detection and quantification, as well as simultaneous assessment of emphysema and coronary artery calcification from a single low-dose CT scan. It provides a multi-modal diagnostic report for a holistic view of thoracic health.
View A View LCS →Choose qXR-CTR if…
Choose qXR-CTR if your primary need is an automated, efficient assessment of heart size and potential heart failure risk directly from chest X-ray images. This tool is specifically designed to quickly and accurately measure the cardiothoracic ratio (CTR), making it suitable for rapid screening and initial evaluation in settings where chest X-rays are the primary imaging modality.
View qXR-CTR →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | A View LCS | qXR-CTR |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker). It can also be integrated into standard reading environments (PACS), RIS (Radiological Information System), or used as a standalone third-party application or web-based application. | Cloud, on-premise, hybrid |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
A View LCSTool A offers a comprehensive and integrated workflow for multiple thoracic analyses from a single CT scan, including automated report generation and CT kernel conversion AI technology, which streamlines the diagnostic process. While Tool B automates a specific measurement, Tool A's broader feature set from one scan potentially simplifies overall clinical workflows and reduces the need for multiple tools.
Clinical Value
A View LCSTool A provides significantly broader clinical value by offering comprehensive thoracic CT analysis for lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. Both tools are FDA-cleared, but Tool B focuses on a single measurement (CTR) from chest X-rays, making Tool A's diagnostic scope more extensive across multiple critical conditions.
Pricing & Value
qXR-CTRBoth tools require direct contact for pricing, indicating a lack of public transparency. However, Tool B (qXR, which includes qXR-CTR) offers a slight advantage by disclosing its pricing model as subscription-based on the number of analyses or installations, providing a clearer understanding of potential cost structures.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements (BAAs). They also provide flexible deployment options including cloud, hybrid, and on-premise/local solutions, indicating equal suitability for integration into diverse healthcare IT environments.
Innovation
A View LCSTool A exhibits greater innovation through its ability to perform comprehensive, multi-disease analysis (lung cancer, emphysema, CAC) from a single low-dose CT scan, incorporating advanced features like CT kernel conversion AI technology. While Tool B's automated CTR measurement is valuable, Tool A's integrated, multi-faceted approach to complex thoracic diagnostics represents a broader innovative step.
Support & Docs
qXR-CTRTool B has a slight edge in this dimension as its broader qXR platform explicitly mentions 'Multilingual support on mobile & web' in addition to user manuals and documentation. Tool A generally refers to technical documentation, but does not specify the same level of accessible support features.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | A View LCS | qXR-CTR |
|---|---|---|
| Product Name | A View LCS | qXR-CTR |
| Company | Coreline Soft Co. | Qure.ai Technologies |
| Tagline | AI-powered medical imaging for comprehensive thoracic disease diagnosis. | AI-powered Chest X-ray Solution for Automated Cardiothoracic Ratio Assessment. |
| Primary Focus | Comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. | Automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. |
| Key AI Features | Automated lung nodule detection and classification, Nodule volume quantification and measurement (3D), Lung-RADS scoring and reporting, Emphysema analysis and quantification (LAA), Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass), Segmentation of major coronary arteries, Automated comprehensive report generation (PDF, DICOM PDF, SR), CT kernel conversion AI technology. | Automates the measurement of the cardiothoracic ratio (CTR). |
| Healthcare Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI, Radiology & Imaging AI |
Videos
Demos, reviews, and walkthroughs featuring A View LCS and qXR-CTR.